Injection of triamicinolone acetonide into the sub-Tenon capsule for treatment of macular edema

Injection of triamicinolone acetonide into the sub-Tenon capsule for treatment of macular edema - Injection of triamicinolone acetonide into the sub-Tenon capsule for treatment of macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000907

Enrollment

Registered

2007-11-27

Start date

2003-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular edema

Interventions

an injection of 12mg or 20mg triamcinolone acetonide into the sub-Tenon capsule

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with macular edema

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Opptical coherence tomography findings (before and after 1 month and 3 months) and visual acuity (before and after 1 month and 3 months)	—

Secondary

Measure	Time frame
Intraocular pressure and cataract progression (before, after 1 week, 2weeks, 1 month, and 3 months), blood glucose level (daily, before and for 1week after injection), HbA1c (before and after 1 month and 3 months) and blood pressure (before and after 1 week)	—

Countries

Japan

Contacts

Public ContactJunko Toda

University of Tokyo School of Medicine Department of Ophthalmology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026